Filing of Form 10-Q for Second Quarter

RNS Number : 6259V

MaxCyte, Inc.

11 August 2022

 

 

MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022

ROCKVILLE, MD, August 11, 2022  - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), aleading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization,today announced that it has filed a Form 10-Q with the SEC for the quarterly period ended June 30, 2022.

A copy of the Form 10-Q is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.

MaxCyte Contacts:

US IR Adviser   Gilmartin Group   David Deuchler, CFA	[phone]   [e-mail]
US Media Relations Seismic Valerie Enes Nominated Adviser and Joint Corporate Broker   Panmure Gordon   Emma Earl / Freddy Crossley   Corporate Broking   Rupert Dearden	[phone] [phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

END

 

 

MSCURVNRURUWAAR